CohBar has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, CohBar, 2017, MAY 13, 2016, View Source [SID1234521269]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

vTv Therapeutics has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, vTv Therapeutics, 2017, MAY 13, 2016, View Source [SID1234521344]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 13, 2016 Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) reported that its co-sponsorship of "Relay for Life Japan" (Organizer: Japan Cancer Society etc.), a charity activity aiming to support cancer patients and their families, and encourage the entire community to confront and conquer cancer throughout the year (Press release, Chugai, MAY 13, 2016, View Sourcenews/detail/20160513150001.html" target="_blank" title="View Sourcenews/detail/20160513150001.html" rel="nofollow">View Source [SID:1234512340]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Starting with Wakayama, Chugai will also display a virtual reality "3D Adventure Experience (Lung Cancer)" aiming to raise public awareness of lung cancer as below. Having visitors participate in "3D Adventure Experience (Lung Cancer)", Chugai appeals the importance of early detection and treatment for lung cancer.

May 14-15: "Relay for Life Japan 2016 in Wakayama (venue: Sunano-maru Square, Wakayama Park)
May 21-22: "Relay for Life Japan 2016 in Ibaraki" (venue: Kenkyu-Gakuen Station Park)
Visitors are able to try "3D Adventure Experience (Lung Cancer)" at the above-mentioned venues. Other venues where visitors can try "3D Adventure Experience (Lung Cancer)", will be sequentially announced at Chugai’s website, "Information from Chugai," (View Source).

Since 2007, Chugai has joined the Relay for Life Japan for 10 years, and has been engaged in the activities to enhance public awareness of cancer. For three years beginning in 2010, a huge balloon art in the shape of a colon, named "Giant Colon," was installed at the venues. Walking inside the tunnel-like balloon art, visitors looked at models and information panels of the internal organs, and became familiar with, and increased their understanding for colon cancer. In 2013 and 2014, visitors had the chance to learn lung cancer through quiz on lung cancer, using the iPad.

Last year, Chugai presented "3D Adventure Experience" where visitors could learn the importance of breast cancer screening. This year, Chugai will continuously offer an event focusing lung cancer to raise awareness of the importance of early detection. We will also hand out brochures for patients (Japanese only) so that visitors can take them home and learn cancer more in depth.

Chugai will organize "Team Chugai" and join each venues of "Relay for Life Japan" to enhance the communication with people who participate in the event across the country. As a leading company in the oncology area, Chugai will work to implement cancer treatment that encourages patients to confront their diseases proactively with hope, offering innovative and useful drugs and information on an ongoing basis, and continue to carry out these activities to contribute to healthcare and the society.

LOAd703 is an adenovirus serotype 5/35 armed with TMZ-CD40L and 4-1BBL (Company Web Page, Lokon Pharma, MAY 13, 2016, View Source [SID:1234512342]). TMZ-CD40L and 4-1BBL are two potent stimulators of anti-tumor immunity by their capacity to activate dendritic cells and M1 macrophages to produce IL12, TNFa, IFNg and IL21, as well as to expand both T cells and NK cells.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 12, 2016 GlobeImmune, Inc. (NASDAQ: GBIM) reported an update on the Company’s business and clinical programs and announced financial results for the first quarter 2016 (Filing, Q1, GlobeImmune, 2016, MAY 12, 2016, View Source [SID:1234512345]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company continues to seek potential strategic transactions. Cantor Fitzgerald & Co. has been retained by the Company to assist in reviewing ways to maximize stockholder value. There is not a defined timeline for the strategic review process and the review may not result in any specific action or transaction.

The Company has three ongoing clinical trials being conducted by the Company’s corporate collaborators, Gilead Sciences, Inc. and Celgene Corporation. GS-US-330-1401, the GS-4774 Phase 2 clinical trial in patients with chronic HBV infection who are currently not receiving treatment, is fully enrolled and the 48-week results are projected to be available in the second half of 2016. The 24-week results for this trial did not show a statistical difference between control and treatment arms. The results from a GI-6207 Phase 2 trial in subjects with medullary thyroid cancer are projected to be available in the second half of 2016. A Phase 2 clinical trial designed to investigate the safety and efficacy of evaluating GI-6301 in combination with radiation therapy in patients with chordoma is still enrolling patients.

Financial Results – First Quarter Ended March 31, 2016

GlobeImmune reported a net loss of $0.9 million for the three months ended March 31, 2016 compared to $1.6 million for the same period in 2015. The decrease in net loss for 2016 was due to lower compensation expense due to layoffs in research and development and general and administrative expenses. GlobeImmune reported a loss applicable to common stockholders of $0.15 per share, for three months ended March 31, 2016 compared to loss applicable to common stockholders of $0.27 per share for the same period in 2015.

Research and development for proprietary programs expense for the three months ended March 31, 2016 was $0.3 million compared to $0.4 million for the same period in 2015, a decrease of $0.1 million. The decrease was primarily due to a decrease in salary expense due to layoffs in 2015. Costs of manufacturing services for the three months ended March 31, 2016 were $0 compared to $0.2 million for the same period in 2015. The decrease was primarily due to a decrease in expenses relating to manufacturing services for Gilead for the Phase 2 HBV trial. Costs of collaboration license and services for the three months ended March 31, 2016 was $0.5 million compared to $0.9 million for the same period in 2015, a decrease of $0.4 million. The decrease was primarily due to a decrease in expenses related to the clinical trial for GS-4774 and reduction in salary expense due to layoffs in 2015. General and administrative expense for the three months ended March 31, 2016 was $0.9 million compared to $1.2 million for the same period in 2015, a decrease of $0.3 million. The decrease was due to a reduction in salary expense due to layoffs in 2015.

At March 31, 2016, GlobeImmune had cash and equivalents of $8.7 million. The Company believes it has sufficient cash to operate the company as a going concern through the middle of 2017 as it continues to evaluate strategic alternatives. If a strategic alternative is not found in the near future, we could decide to wind down the operations of the Company which will consume cash faster than currently planned as a going concern.